Fibroblasts mediate endothelium response to angiogenic cues in a newly developed 3D stroma engineered model
Source abstract
Abstract
Three-dimensional stroma engineered models would enable fundamental and applicative studies of human tissues interaction and remodeling in both physiological and pathological conditions. In this work, we propose a 3D vascularized stroma model to be used as in vitro platform for drug testing. A pullulan/dextran-based porous scaffold containing pre-patterned microchannels of 100 μm diameter is used for co-culturing of fibroblasts within the matrix pores and endothelial cells to form the lumen. Optical clearing of the constructs by hyperhydration allows for in-depth imaging of the model up to 1 mm by lightsheet and confocal microscopy. Our 3D vascularized stroma model allows for higher viability, metabolism and cytokines expression compared to a monocultured vascular model. Stroma-endothelium cross-talk is then investigated by exposing the system to pro and anti-angiogenic molecules. The results highlight the protective role played by fibroblasts on the vasculature, as demonstrated by decreased cytotoxicity, restoration of nitric oxide levels upon challenge, and sustained expression of endothelial markers CD31, vWF and VEGF. Our tissue model provides a 3D engineered platform for in vitro studies of stroma remodeling in angiogenesis-driven events, known to be a leading mechanism in diseased conditions, such as metastatic cancers, retinopathies and ischemia, and to investigate related potential therapies.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Angiogenesis and VEGF in Cancer · Cancer Cells and Metastasis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. In vitro strategies to vascularize 3D physiologically relevant models
2. Vascularization in tissue engineering10.1016/j.tibtech.2008.04.009 ↗
3. Vascularization and angiogenesis in tissue engineering: beyond creating static networks10.1016/j.tibtech.2016.03.002 ↗
4. Vasculature-on-a-chip for in vitro disease models
5. Engineering of functional, perfusable 3D microvascular networks on a chip10.1039/c3lc41320a ↗
6. Three-dimensional bioprinting of thick vascularized tissues10.1073/pnas.1521342113 ↗
7. Advances in on-chip vascularization10.2217/rme-2016-0152 ↗
8. Alternative origins of stroma in normal organs and disease10.1016/j.scr.2011.11.005 ↗
9. Multicellular 3D models to study tumour-stroma interactions10.3390/ijms22041633 ↗
10. 3D in vitro model (R)evolution: unveiling tumor–stroma interactions10.1016/j.trecan.2020.10.009 ↗
11. Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation10.1073/pnas.1417115112 ↗
12. Fibroblast sheets co-cultured with endothelial progenitor cells improve cardiac function of infarcted hearts10.1007/s10047-008-0421-8 ↗
13. Integration of blood outgrowth endothelial cells in dermal fibroblast sheets promotes full thickness wound healing10.1002/stem.445 ↗
14. Adipose extracellular matrix/stromal vascular fraction gel: a novel adipose tissue–derived injectable for stem cell therapy10.1097/PRS.0000000000003214 ↗
15. Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models10.1158/0008-5472.CAN-14-1809 ↗
16. A novel scaffold-based hybrid multicellular model for pancreatic ductal adenocarcinoma—toward a better mimicry of the in vivo tumor microenvironment10.3389/fbioe.2020.00290 ↗
17. A versatile 3D tissue matrix scaffold system for tumor modeling and drug screening
18. Engineered human liver based on pullulan-dextran hydrogel promotes mice survival after liver failure
19. Tuning physicochemical properties of a macroporous polysaccharide-based scaffold for 3D neuronal culture10.3390/ijms222312726 ↗
20. Spatial-controlled coating of pro-angiogenic proteins on 3D porous hydrogels guides endothelial cell behavior10.3390/ijms232314604 ↗
21. Development of 3D hepatic constructs within polysaccharide-based scaffolds with tunable properties10.3390/ijms21103644 ↗
22. Channeled polysaccharide-based hydrogel reveals influence of curvature to guide endothelial cell arrangement in vessel-like structures10.1016/j.msec.2020.111369 ↗
23. Fabrication of porous polysaccharide-based scaffolds using a combined freeze-drying/cross-linking process10.1016/j.actbio.2010.03.004 ↗
24. Le Visage
25. 3D porous collagen scaffolds reinforced by glycation with ribose for tissue engineering application10.1088/1748-605X/aa7694 ↗
26. A 3D pancreatic tumor model to study T cell infiltration10.1039/D1BM00210D ↗
27. Broad applicability of a streamlined ethyl cinnamate-based clearing procedure
28. UbasM: an effective balanced optical clearing method for intact biomedical imaging10.1038/s41598-017-12484-3 ↗
29. Fiji: an open-source platform for biological-image analysis10.1038/nmeth.2019 ↗
30. Recent insights on applications of pullulan in tissue engineering10.1016/j.carbpol.2016.07.118 ↗
31. Engineering dextran-based scaffolds for drug delivery and tissue repair10.2217/nnm.12.149 ↗
32. Microfluidic techniques for development of 3D vascularized tissue10.1016/j.biomaterials.2014.04.091 ↗
33. Microfluidic approaches for engineering vasculature10.1016/j.coche.2013.10.006 ↗
34. Microfluidic Biomaterials10.1002/adhm.202001028 ↗
35. Development of 3D hepatic constructs within polysaccharide-based scaffolds with tunable properties10.3390/ijms21103644 ↗
36. Engineered pullulan–collagen composite dermal hydrogels improve early cutaneous wound healing10.1089/ten.tea.2010.0298 ↗
37. HLC/pullulan and pullulan hydrogels: their microstructure, engineering process and biocompatibility10.1016/j.msec.2015.09.039 ↗
38. Crosslinked pullulan/cellulose acetate fibrous scaffolds for bone tissue engineering10.1016/j.msec.2016.08.015 ↗
39. The role of matrix stiffness in cancer stromal cell fate and targeting therapeutic strategies10.1016/j.actbio.2022.08.005 ↗
40. The stiffness of living tissues and its implications for tissue engineering10.1038/s41578-019-0169-1 ↗
41. Markers and biomarkers of endothelium: when something is rotten in the state10.1155/2017/9759735 ↗
42. Dellaquila · 2021
43. Modulation of extracellular matrix proteins by endothelial cells undergoing angiogenesis in vitro10.1161/01.ATV.11.4.805 ↗
44. Surface markers distinguishing mesenchymal stem cells from fibroblasts10.6001/actamedica.v19i2.2313 ↗
45. Defining skin fibroblastic cell types beyond CD9010.3389/fcell.2018.00133 ↗
46. Pore alignment in gelatin scaffolds enhances chondrogenic differentiation of infrapatellar fat pad derived mesenchymal stromal cells10.1021/acsbiomaterials.8b00246 ↗
47. The effect of anisotropic collagen-GAG scaffolds and growth factor supplementation on tendon cell recruitment, alignment, and metabolic activity10.1016/j.biomaterials.2011.04.021 ↗
48. Cell sheet tissue engineering: cell sheet preparation, harvesting/manipulation, and transplantation10.1002/jbm.a.36627 ↗
49. The plot thickens: the emerging role of matrix viscosity in cell mechanotransduction10.1002/adhm.201901259 ↗
50. Incorporation of a matrix metalloproteinase-sensitive substrate into self-assembling peptides – a model for biofunctional scaffolds10.1016/j.biomaterials.2007.11.046 ↗
51. The use of optical clearing and multiphoton microscopy for investigation of three-dimensional tissue-engineered constructs10.1089/ten.tec.2013.0538 ↗
52. Imaging challenges in biomaterials and tissue engineering10.1016/j.biomaterials.2013.05.033 ↗
53. 3D imaging of tissue integration with porous biomaterials10.1016/j.biomaterials.2008.06.018 ↗
54. Integration of optical clearing and optical sectioning microscopy for three-dimensional imaging of natural biomaterial scaffolds in thin sections10.1117/1.3158998 ↗
55. Tumour cell invasiveness and response to chemotherapeutics in adipocyte invested 3D engineered anisotropic collagen scaffolds10.1038/s41598-018-30107-3 ↗
56. Clarifying tissue clearing10.1016/j.cell.2015.06.067 ↗
57. Physical and chemical mechanisms of tissue optical clearing10.1016/j.isci.2021.102178 ↗
58. L-arginine/5-fluorouracil combination treatment approaches cells selectively: rescuing endothelial cells while killing MDA-MB-468 breast cancer cells10.1016/j.fct.2018.11.018 ↗
59. Cardiac ischemia on-a-chip to investigate cellular and molecular response of myocardial tissue under hypoxia10.1016/j.biomaterials.2021.121336 ↗
60. Comparison of the effects between bevacizumab and mitomycin C on the survival of fibroblasts10.3341/jkos.2011.52.3.345 ↗
61. Integrated on-chip 3D vascular network culture under hypoxia10.3390/mi11050475 ↗
62. A biomimetic 3D model of hypoxia-driven cancer progression10.1038/s41598-019-48701-4 ↗
63. Nitric oxide and angiogenesis10.1023/A:1006431309841 ↗
64. Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis10.18388/abp.2003_3713 ↗
65. Enhancement of VEGF-mediated angiogenesis by 2-N,6-O-sulfated chitosan-coated hierarchical PLGA scaffolds10.1021/acsami.5b02324 ↗
66. Role of L-arginine in nitric oxide production in health and hypertension10.1111/j.1440-1681.2008.05123.x ↗
67. The pharmacodynamics of L-arginine10.1093/jn/137.6.1650S ↗
68. The clinical pharmacology of L-arginine10.1146/annurev.pharmtox.41.1.79 ↗
69. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer10.1038/nrd1381 ↗
70. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook10.1016/j.ctrv.2020.102017 ↗
71. A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs10.1039/C4LC00866A ↗
72. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-110.1182/blood-2004-07-2958 ↗
73. Regulation of cell proliferation by hypoxia-inducible factors10.1152/ajpcell.00279.2015 ↗
74. Continuous perivascular l-arginine delivery increases total vessel area and reduces neointimal thickening after experimental balloon dilatation10.1161/01.ATV.19.3.767 ↗
75. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids10.1007/s11060-010-0357-8 ↗
76. Effects of hypoxia on cardiomyocyte proliferation and association with stage of development10.1016/j.biopha.2019.109391 ↗
77. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma10.1167/iovs.09-4755 ↗
78. Effect of bevacizumab on postoperative adhesion formation in a rat uterine horn adhesion model and the correlation with vascular endothelial growth factor and Ki-67 immunopositivity10.1016/j.fertnstert.2011.02.005 ↗
79. Bevacizumab modulates epithelial-to-mesenchymal transition in the retinal pigment epithelial cells via connective tissue growth factor up-regulation10.1111/j.1755-3768.2012.02426.x ↗
80. Critical role of l-arginine in endothelial cell survival during oxidative stress10.1161/01.CIR.0000066909.13953.F1 ↗
81. Effects of intravitreal injection of bevacizumab on nitric oxide levels10.1038/eye.2014.297 ↗
82. Effect of bevacizumab on survival and production of nitric oxide in trabecular meshwork cells10.3341/jkos.2009.50.9.1404 ↗
83. Anastomosis of endothelial sprouts forms new vessels in a tissue analogue of angiogenesis10.1039/c2ib20061a ↗
84. A microfluidic platform for quantitative analysis of cancer angiogenesis and intravasation10.1063/1.4894595 ↗
85. Reactive oxygen species levels in human retinal pigment epithelium cells in vitro to anti-VEGF agents: ranibizumab, bevacizumab, aflibercept and Ziv-aflibercept
86. Sources of vascular nitric oxide and reactive oxygen species and their regulation10.1152/physrev.00036.2017 ↗
87. Gene expression profile and Angiogenic markers correlate with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer10.1158/1078-0432.CCR-07-4762 ↗
88. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma10.1167/iovs.09-4755 ↗
89. Enhanced expression of CD31/platelet endothelial cell adhesion molecule 1 (PECAM1) correlates with hypoxia inducible factor-1 alpha (HIF-1α) in human glioblastoma multiforme10.1016/j.yexcr.2015.09.007 ↗
90. Hypoxia induces endothelial-mesenchymal transition in pulmonary vascular remodeling
91. Bevacizumab modulates the process of fibrosis in vitro10.1111/ceo.12374 ↗
92. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells10.1182/blood-2005-09-3541 ↗
93. Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis
94. Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor
95. Chinot · 2016
96. Tabouret · 2015
97. Role of Interleukin-8 in tumor growth and metastasis of human melanoma10.1159/000028045 ↗
98. Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation10.1093/rheumatology/keu254 ↗
99. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts10.1038/sj.bjc.6690357 ↗
100. Matrix metalloproteinases: regulators of the tumor microenvironment10.1016/j.cell.2010.03.015 ↗